BRPI0511603A - método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados - Google Patents
método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatadosInfo
- Publication number
- BRPI0511603A BRPI0511603A BRPI0511603-1A BRPI0511603A BRPI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A BR PI0511603 A BRPI0511603 A BR PI0511603A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- disorders
- nasps
- sulfated polysaccharides
- bleeding disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
MéTODO PARA O TRATAMENTO DE DISTúRBIOS DO SANGRAMENTO COM A UTILIZAçãO DE POLISSACARìDEOS SULFATADOS. São revelados para o tratamento de distúrbios do sangramento com a utilização de polissacarídeos sulfatados não anticoagulantes (NASPs) como pró-coagulantes. NASPs podem ser administrados como agentes únicos, ou em combinação com outros, ou com outras medicações (tais como fatores VII, VIII e IX) para promover hemostasia. Em particular, é descrito o uso de NASPS no tratamento de distúrbios do sangramento, incluindo distúrbios da coagulação congênitos, distúrbios da coagulação adquiridos e condições hemorrágicas induzidas por trauma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57484504P | 2004-05-27 | 2004-05-27 | |
PCT/US2005/018669 WO2005117912A1 (en) | 2004-05-27 | 2005-05-27 | Methods for treating bleeding disorders using sulfated polysaccharides |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511603A true BRPI0511603A (pt) | 2008-01-02 |
Family
ID=35462725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511603-1A BRPI0511603A (pt) | 2004-05-27 | 2005-05-27 | método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados |
Country Status (16)
Country | Link |
---|---|
US (4) | US7767654B2 (pt) |
EP (2) | EP2165711B1 (pt) |
JP (2) | JP5232470B2 (pt) |
CN (2) | CN103251647A (pt) |
AU (1) | AU2005249465B2 (pt) |
BR (1) | BRPI0511603A (pt) |
CA (1) | CA2567495C (pt) |
CY (1) | CY1113705T1 (pt) |
DK (1) | DK1748781T3 (pt) |
ES (2) | ES2482105T3 (pt) |
HK (2) | HK1103624A1 (pt) |
PL (1) | PL1748781T3 (pt) |
PT (1) | PT1748781E (pt) |
RU (1) | RU2347574C2 (pt) |
SI (1) | SI1748781T1 (pt) |
WO (1) | WO2005117912A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
ES2482105T3 (es) * | 2004-05-27 | 2014-08-01 | Baxter International Inc. | Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados |
US20080107678A1 (en) * | 2006-04-27 | 2008-05-08 | Johnson Kirk W | Method for treating thrombotic disorders using sulfated polysaccharides |
EP3409694A1 (en) * | 2007-02-23 | 2018-12-05 | Baxalta GmbH | Process methods for fucoidan purification from seaweed extracts |
US9956272B2 (en) * | 2007-05-30 | 2018-05-01 | Bio Products Laboratory Limited | Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same |
WO2009061697A1 (en) | 2007-11-09 | 2009-05-14 | The Board Of Trustees Of The University Of Illinois | Anticoagulant antagonist and hemophilia procoagulant |
CA2731304C (en) * | 2008-08-22 | 2017-06-06 | Baxter Healthcare S.A. | Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides |
CA2746257C (en) * | 2008-12-11 | 2018-01-16 | Baxter International Inc. | Preparations based on fibrinogen and sulfated polysaccharides |
NZ607892A (en) | 2008-12-19 | 2014-11-28 | Baxter Int | Tfpi inhibitors and methods of use |
JP6393453B2 (ja) * | 2010-01-14 | 2018-09-19 | バクスアルタ ゲーエムベーハー | 出血性障害を治療するための方法及び組成物 |
EP2547355B1 (en) | 2010-03-19 | 2017-01-11 | Baxalta GmbH | Tfpi inhibitors and methods of use |
KR102049254B1 (ko) * | 2010-04-20 | 2019-11-28 | 옥타파마 아게 | 약학 단백질을 위한 신규한 안정화제 |
EP2624859B1 (en) | 2010-10-06 | 2017-03-01 | Medimmune Limited | Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy |
WO2013012954A2 (en) * | 2011-07-19 | 2013-01-24 | Baxter International Inc. | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
JP6228137B2 (ja) | 2012-01-30 | 2017-11-08 | バクスアルタ ゲーエムベーハー | 非抗凝固性の硫酸化またはスルホン酸化多糖 |
EP2809330B1 (en) * | 2012-01-30 | 2019-06-12 | Baxalta GmbH | Non-anticoagulant sulfated or sulfonated synthetic polymers |
NZ629130A (en) | 2012-03-21 | 2016-10-28 | Baxalta Inc | Tfpi inhibitors and methods of use |
RU2472495C1 (ru) * | 2012-05-05 | 2013-01-20 | Илья Николаевич Медведев | Способ нормализации уровня альфа2-антиплазмина у свиноматок с бронхитом |
EP2662083A1 (en) | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
DK2885642T3 (da) * | 2012-08-14 | 2019-07-29 | Baxalta GmbH | Fremgangsmåder og systemer til screening af sammensætninger omfattende ikke-antikoagulerende sulfaterede polysaccharider |
CN103610684B (zh) * | 2013-11-07 | 2016-04-06 | 苏州大学 | 糖类在制备治疗血小板数量相关疾病的药物中的应用 |
JP6225321B1 (ja) | 2016-08-31 | 2017-11-08 | 王子ホールディングス株式会社 | ポリ硫酸ペントサンの製造方法 |
BR112020003908B1 (pt) | 2016-08-31 | 2023-01-24 | Oji Holdings Corporation | Método para produzir um ingrediente farmacêutico ativo incluindo polissulfato de pentosano |
JP6281659B1 (ja) | 2017-02-28 | 2018-02-21 | 王子ホールディングス株式会社 | ポリ硫酸ペントサン、医薬組成物及び抗凝固剤 |
BR112019025030A2 (pt) | 2017-05-31 | 2020-06-16 | Oji Holdings Corporation | Preparação umidificante tópica. |
AU2018333249B2 (en) | 2017-09-12 | 2023-03-02 | Oji Holdings Corporation | Pentosan polysulfate and method for producing pentosan polysulfate |
MX2020006605A (es) | 2017-12-20 | 2020-09-10 | Oji Holdings Corp | Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano. |
CN108822231A (zh) * | 2018-06-29 | 2018-11-16 | 桂林理工大学 | 一种具有提高抗氧化活性的果胶多糖硫酸化修饰产物及其制备方法 |
SE1950885A1 (en) * | 2019-07-11 | 2021-01-12 | Faelker Knut | Treatment of patients undergoing antiplatelet medication experiencing acute bleeding complications during / after surgery |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
IL85145A (en) * | 1987-01-23 | 1994-08-26 | Univ Australian | Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity |
JP3094165B2 (ja) * | 1990-11-05 | 2000-10-03 | バクスター、ダイアグノスチックス、インコーポレイテッド | 抗凝固剤濃度測定方法 |
JP3714426B2 (ja) | 1994-02-01 | 2005-11-09 | 株式会社糖鎖工学研究所 | フコイダンオリゴ糖組成物含有癌転移抑制剤 |
JP3605414B2 (ja) * | 1995-04-28 | 2004-12-22 | タカラバイオ株式会社 | 糖化合物 |
FR2754183A1 (fr) * | 1996-10-08 | 1998-04-10 | Lefebvre Jean Marie | Composition visqueuse hemostatique, notamment a l'etat de gel |
US6426192B1 (en) * | 1997-04-25 | 2002-07-30 | Pentapharm Ag | Method for the functional detection of disorders in the protein C system |
UA65587C2 (en) * | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
KR100727339B1 (ko) * | 1999-04-15 | 2007-06-12 | 다카라 바이오 가부시키가이샤 | 치료제 |
AU2001244602A1 (en) * | 2000-03-30 | 2001-10-15 | Ajinomoto Co. Inc. | Drugs retained in target tissue over long time |
ES2301624T3 (es) * | 2001-02-05 | 2008-07-01 | Novo Nordisk Health Care Ag | Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii. |
US20030203845A1 (en) * | 2001-02-05 | 2003-10-30 | Knudsen Jens Bjerre | Combined use of factor VII polypeptides and factor IX polypeptides |
ES2236420T3 (es) * | 2001-10-24 | 2005-07-16 | Takara Bio Inc. | Oligosacarido de fucano sulfatado. |
JP3941036B2 (ja) * | 2001-12-07 | 2007-07-04 | サンスター株式会社 | 経口投与のためのリポソーム組成物 |
DE10309368A1 (de) * | 2002-08-06 | 2004-02-26 | Aventis Behring Gmbh Intellectual Property/Legal | Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase |
IL152030A0 (en) * | 2002-09-30 | 2003-05-29 | Nvr Labs Ltd Neural & Vascular | Cohesive biopolymers comprising sulfated polysaccharides and fibrillar proteins and use thereof for tissue repair |
JP2004144580A (ja) * | 2002-10-23 | 2004-05-20 | Japan Clinical Laboratories Inc | 血液凝固検査方法 |
US20050033029A1 (en) * | 2003-06-30 | 2005-02-10 | Jin Lu | Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
ES2482105T3 (es) * | 2004-05-27 | 2014-08-01 | Baxter International Inc. | Procedimientos de tratamiento de trastornos hemorrágicos utilizando polisacáridos sulfatados |
US20080107678A1 (en) | 2006-04-27 | 2008-05-08 | Johnson Kirk W | Method for treating thrombotic disorders using sulfated polysaccharides |
-
2005
- 2005-05-27 ES ES09180857.6T patent/ES2482105T3/es active Active
- 2005-05-27 EP EP09180857.6A patent/EP2165711B1/en active Active
- 2005-05-27 PT PT57659500T patent/PT1748781E/pt unknown
- 2005-05-27 AU AU2005249465A patent/AU2005249465B2/en active Active
- 2005-05-27 CN CN2013101636132A patent/CN103251647A/zh active Pending
- 2005-05-27 CN CN2005800236583A patent/CN1984664B/zh active Active
- 2005-05-27 PL PL05765950T patent/PL1748781T3/pl unknown
- 2005-05-27 DK DK05765950.0T patent/DK1748781T3/da active
- 2005-05-27 WO PCT/US2005/018669 patent/WO2005117912A1/en active Application Filing
- 2005-05-27 ES ES05765950T patent/ES2399277T3/es active Active
- 2005-05-27 EP EP05765950A patent/EP1748781B1/en active Active
- 2005-05-27 SI SI200531664T patent/SI1748781T1/sl unknown
- 2005-05-27 RU RU2006146801/15A patent/RU2347574C2/ru not_active IP Right Cessation
- 2005-05-27 BR BRPI0511603-1A patent/BRPI0511603A/pt not_active IP Right Cessation
- 2005-05-27 US US11/140,504 patent/US7767654B2/en active Active
- 2005-05-27 CA CA2567495A patent/CA2567495C/en active Active
- 2005-05-27 JP JP2007515373A patent/JP5232470B2/ja active Active
-
2007
- 2007-07-20 HK HK07107845.5A patent/HK1103624A1/xx unknown
-
2009
- 2009-04-13 US US12/386,026 patent/US7829549B2/en active Active
-
2010
- 2010-09-16 HK HK10108794.9A patent/HK1142276A1/xx unknown
- 2010-09-29 US US12/893,798 patent/US8859526B2/en active Active
-
2011
- 2011-05-19 US US13/111,746 patent/US8771973B2/en active Active
- 2011-12-05 JP JP2011266214A patent/JP2012046551A/ja active Pending
-
2013
- 2013-02-21 CY CY20131100157T patent/CY1113705T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511603A (pt) | método para o tratamento de distúrbios do sangramento com a utilização de polissacarìdeos sulfatados | |
Pereira et al. | Influence of Aloe vera on water absorption and enzymatic in vitro degradation of alginate hydrogel films | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
BRPI0306993B8 (pt) | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível | |
MX2009001323A (es) | Aposito solido para tratar tejido herido. | |
ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
PH12013501791B1 (en) | Uses of dpp-iv inhibitors | |
WO2009040420A3 (en) | Use of a monoterpene to increase tissue repair | |
BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
WO2007007098A3 (en) | Promotion of epithelial regeneration | |
DE502007002101D1 (de) | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen | |
DE60313597D1 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
ATE376835T1 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
WO2007038686A3 (en) | Amniotic membrane preparations and purified compositions and methods of use | |
MX2010003019A (es) | Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia. | |
EP2497478A3 (en) | Oligosaccaride compositions and use thereof in the treatment of infection | |
ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
WO2007098114A3 (en) | Clotting and healing compositions containing keratin biomaterials | |
BR112016009954A2 (pt) | terapia para o tratamento ou prevenção de condições associadas a sangramento hipocoagulação | |
WO2009081408A3 (en) | Pulverized fibrin clots and pharmaceutical compositions containing them | |
AU1865100A (en) | Hyaluronate lyase used for promoting penetration in topical agents | |
HK1112721A1 (en) | Tissue disruption treatment and composition for use thereof | |
BRPI0516134A (pt) | neurotoxinas de clostridium para uso na cicatrização de tecidos | |
Budko et al. | Local hemostatic agents and ways of their improvement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |